Cancer Network interviews two prominent ovarian cancer researchers from both sides of the Atlantic on the role of PARP inhibitors and the challenges of developing ovarian cancer therapies.
Jonathan Ledermann, MD
Advertisement
Articles by Jonathan Ledermann, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
MYTHIC Trial Demonstrates Efficacy in Platinum-Resistant Ovarian Cancer
2
FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma
3
FDA OKs Oral Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
4
Zoldonrasib Shows Promising Activity in KRAS G12D+ NSCLC
5